A pharmaceutical executive collapsed during a press conference in the Oval Office today, contrary to initial reports linking the incident to Novo Nordisk executive Gordon Finlay. The man, whose identity remains unknown, fell while standing behind the US president as the Trump administration unveiled a new deal for weight-loss medications.
Officials and representatives from the pharmaceutical industry rushed to assist the man to prevent him from falling. White House Press Secretary Karoline Leavitt clarified that a representative from one of the companies participating in the ‘Most Favored Nations Oval Office Announcement’ had fainted. Medical personnel on-site attended to the individual, confirming his well-being, and the press conference was expected to resume shortly.
Following the incident, reporters were asked to leave the Oval Office while cabinet members attended to the collapsed individual, elevating his legs. The cause of the collapse remains unknown at this time.
The press conference featured executives from drug companies Novo Nordisk and Eli Lilly alongside the Trump administration, introducing a groundbreaking deal that could revolutionize the healthcare sector. The agreement involves the availability of sought-after treatments like Ozempic, Wegovy, and Zepbound directly to the public through TrumpRx, a forthcoming government website.
As part of the plan, the companies aim to offer an oral version of the medications at a monthly cost of $149 (£113) pending FDA approval. Furthermore, individuals on Medicare or Medicaid with approved conditions will benefit from a reduced price of $245 (£186) per month for the injectable versions, marking a significant victory for patients.
